Studies with Hydroxyurea II. Prolonged Exposure of Escherichia coli to Hydroxyurea
نویسندگان
چکیده
منابع مشابه
Hydroxyurea and Escherichia coli nucleoside diphosphate reductase.
M). The cultures were incubated at 37° for 40 mm (“Pretreatment―), whereupon the bacteria were washed and resuspended in fresh Medium HA. Portions from each culture were distributed into flasks containing premeasured amounts of the various drugs (“Additions―). After receiving cytidine-3H (2 @ig/ml; 0.13 i@Ci/ml),the cultures were incubated with aeration at 37°for 20 mm and quadr.uplic...
متن کاملHydroxyurea induces hydroxyl radical-mediated cell death in Escherichia coli.
Hydroxyurea (HU) specifically inhibits class I ribonucleotide reductase (RNR), depleting dNTP pools and leading to replication fork arrest. Although HU inhibition of RNR is well recognized, the mechanism by which it leads to cell death remains unknown. To investigate the mechanism of HU-induced cell death, we used a systems-level approach to determine the genomic and physiological responses of ...
متن کاملPhotodermatosis secondary to hydroxyurea.
To cite: Yanamandra U, Sahu KK, Malhotra P, et al. BMJ Case Rep Published online: [please include Day Month Year] doi:10.1136/ bcr-2014-205974 DESCRIPTION A middle aged Southeast-Asian man, recently diagnosed with chronic myeloid leukaemia (Philadelphia positive on FISH), was started on cytoreductive therapy with hydroxyurea due to high leucocyte count (130 000/mL). The patient had no history o...
متن کاملAcquired DNA mutations associated with in vivo hydroxyurea exposure.
Hydroxyurea (HU) is an effective therapeutic agent for patients with myeloproliferative disorders (MPDs) or sickle cell disease (SCD). Short-term HU toxicities primarily include transient myelosuppression, but long-term HU risks have not been defined. The mutagenic and carcinogenic potential of HU is not established, although HU has been associated with an increased risk of leukemia in some pat...
متن کاملENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
BACKGROUND Hydroxyurea (HU) is the only disease-modifying medication for patients with sickle cell disease (SCD). HU can reduce SCD-related complications but only 35% to 50% of pediatric patients adhere to HU at the rates achieved in clinical trials and this limits its clinical effectiveness. Mobile Directly Observed Therapy (Mobile DOT) is a pilot-tested, electronic, multidimensional, HU adher...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Bacteriology
سال: 1966
ISSN: 0021-9193,1098-5530
DOI: 10.1128/jb.92.1.178-185.1966